Bad cholesterol, beware! Aegerion Pharmaceuticals is hot on your trail. The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Aegerion's first approved drug is Juxtapid (lomitapide, branded Lojuxta in Europe), a protein inhibitor that blocks cholesterol production in the liver and intestine. The firm is working on getting Juxtapid approved in Japan and for children and teens. Aegerion also markets Myalept, a treatment for leptin deficiency. In November 2016, Aegerion was acquired by Canada's QLT (which then renamed itself Novelion Therapeutics).